Polycystic Ovary Syndrome (PCOS) is the most common endocrine disorder among women of reproductive age, characterized by its chronic and complex nature. This condition is marked by a combination of ovarian dysfunction and symptoms related to excess androgen, often classified as heterogeneous due to its varied manifestations. PCOS poses significant public health challenges, as it is associated with multiple long-term metabolic issues and a range of comorbidities. The prevalence of PCOS appears to be rising, underscoring the need for effective management strategies.
Research indicates that certain medications may be beneficial for managing PCOS symptoms. These include thiazolidinedione’s, dipeptide peptidase-4 inhibitors, GLP-1 receptor agonists, SGLT-2 inhibitors, HMG-CoA reductase inhibitors, mucolytic agents, and various dietary supplements. However, there is a pressing need for further studies, including well-designed clinical trials involving diverse populations and clearly defined outcomes. Gaining a deeper understanding of PCOS will enable researchers to explore new therapeutic avenues and potentially develop innovative treatments targeting previously unrecognized pathways.